{"nctId":"NCT00712348","briefTitle":"Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase","startDateStruct":{"date":"2008-12"},"conditions":["Gaucher Disease"],"count":31,"armGroups":[{"label":"Taliglucerase alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Taliglucerase alfa"]}],"interventions":[{"name":"Taliglucerase alfa","otherNames":["Plant cell expressed recombinant glucocerebrosidase (prGCD)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females, 2 years or older\n* Confirmed diagnosis of Gaucher disease by the enzymatic activity assay\n* Stable Gaucher disease\n* Treatment with imiglucerase (Cerezyme®) for at least 2 years and on a stable maintenance regimen (dose and regimen unchanged, except for situation of drug shortage) for at least the last six months\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Currently taking another experimental drug for any condition\n* History of allergy to carrots\n* History of allergy to beta lactam antibiotics\n* Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions\n* Presence of HIV and/or HBsAg and/or hepatitis C infection\n* Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency\n* Presence of any significant comorbidity that could confound the interpretation of the clinical response to taliglucerase alfa\n* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"OTHER_PRE_SPECIFIED","title":"Platelet Count","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161137","spread":"73387"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150800","spread":"66038"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157586","spread":"78357"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161167","spread":"80820"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Spleen Volume","description":"Spleen volume measured by MRI in mL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"720.5","spread":"579.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"654.7","spread":"535.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Liver Volume","description":"Liver volume measured by MRI","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1766","spread":"474.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1716","spread":"455.6"}]}]}]},{"type":"PRIMARY","title":"Hemoglobin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"1.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":31},"commonTop":["NASOPHARYNGITIS","INFUSION RELATED REACTION","ARTHRALGIA","HEADACHE","UPPER RESPIRATORY TRACT INFECTION"]}}}